deaths from heart disease have already declined over 50%, and simple interventions like GLP-1 agonists have already made huge progress against obesity and diabetes.
This is a textbook example of the “Era of the Ideological Investor,” where model-driven fundamental analysis becomes irrelevant once the government emerges as the largest sponsor of idiosyncratic dispersion in capital markets. The path to outperformance is no longer better spreadsheets—it is anticipation